NLS Pharma News

Burkholderia cepacia Complex: Rising Risk for Microbiological Quality and USP Compliance

The Burkholderia cepacia complex (BCC) has become a major concern in pharmaceutical microbiology due to its resistance to preservatives and ability to persist in aqueous products.

Agreement – October 23, 2025

Medivir enters licensing agreement with Biossil

Medivir has entered into an exclusive licensing agreement, through which Biossil, Inc. will receive global, exclusive development rights for remetinostat, a clinical-stage topical HDAC inhibitor.

Clinical trial supplies with speed and agility

Stockholm-based ClinStorage is a one-stop-shop for small to medium-sized clinical trial sponsors. The GMP-licensed company prides itself on being fast, agile, and cost-effective, and its offering includes GMP storage, clinical services, and QP/QA consultations.

Pharma Business – October 16, 2025

Novo Nordisk and Omeros enter purchase and license agreement

The companies have entered into a definitive asset purchase and license agreement for the candidate drug zaltenibart (formerly OMS906) in clinical development for rare blood and kidney disorders.

Pharma Business – October 15, 2025

Lundbeck receives Breakthrough Therapy Designation in China

The company’s investigational drug bexicaserin, for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs), has been granted Breakthrough Therapy Designation (BTD) by China’s Center for Drug Evaluation (CDE).

Clinical Trials

Clinical Trials – October 22, 2025

ACORAI presents positive results

The company has announced results from the 1,600-patient CAPTURE-HF study (Machine-Learning Estimation of Pulmonary Capillary Wedge and Right Atrial Pressures With a Non-Invasive Multi-sensor Device).

Biotech Business – October 22, 2025

Abera reports long-term data for its nasal influenza vaccine

The results show that the vaccine generates strong and long-lasting immune responses both at the mucosal surfaces and systemically.

Clinical Trials – October 20, 2025

Aqilion announces new clinical pharmacokinetic study results

The company has announced positive results from the ARIA-2 clinical study.

Clinical Trials – October 10, 2025

Herantis announces positive data for HER-096 in Phase 1b trial

Herantis Pharma has announced positive topline results from its Phase 1b trial of HER-096 in people living with Parkinson’s disease, with all primary and secondary endpoints met.

Clinical Trials – October 8, 2025

PharmNovo secures CTA approval in Spain

The company’s clinical trial application (CTA) for a Phase IIa proof of concept (PoC) study investigating the safety and efficacy of lead candidate PN6047 in patients with neuropathic pain has been approved in Spain.

Clinical Trials – October 1, 2025

Gesynta Pharma receives UK approval for a Phase 2 trial

The company’s clinical trial application for the company’s Phase 2 trial of vipoglanstat for the treatment of endometriosis has been approved by the UK authorities.

Clinical Trials – September 25, 2025

Hansa Biopharma’s imlifidase meets primary endpoint in Phase 3 trial

The company has announced positive topline results from the US Phase 3 ConfIdeS trial of imlifidase, evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) adult kidney transplant patients with positive crossmatch against a deceased donor, versus the control arm.

Clinical Trials – September 24, 2025

New study aims to provide more cancer patients with targeted treatment

The new, national study uses genetic analysis of tumors to match cancer patients with targeted drugs – even when these are not yet approved for their specific diagnosis.

Clinical Trials – September 17, 2025

AnaCardio completes target enrollment in Phase 2a study

AnaCardio has announced that its ongoing Phase 2a study of AC01 in patients with heart failure and reduced ejection fraction (HFrEF) is fully enrolled and remains on track to report results by year-end 2025.

Clinical Trials – September 15, 2025

Cinclus Pharma screens first patient in Phase III trial

The first patient has been screened in the company’s HEEALING 1 Phase III trial evaluating linaprazan glurate for the treatment of erosive gastroesophageal reflux disease (GERD).

Profiles in Pharma

Profiles in Pharma – April 2, 2025

The Jalkanens: A shared thirst for knowledge

For Sirpa and Markku Jalkanen of Finland, M.D. and Ph.D., married, immunotherapy researchers, working together came as naturally as a courtship.

Profiles in Pharma – November 1, 2023

Jonina Gudmundsdottir, Coripharma

In the heart of Iceland’s life sciences industry, Jonina Gudmundsdottir, the CEO of Coripharma, is making her mark. With a deep understanding of the industry’s challenges and a relentless drive for excellence, Gudmundsdottir has steered Coripharma toward transformative success. Iceland’s life sciences industry has thrived in recent years, propelled by its unique strengths. With a […]

Profiles in Pharma – July 3, 2023

Deborah Dunsire

The CEO of Lundbeck, who announced that she will retire last week, did not initially intend to join the life science industry, but it captivated her more than 30 years ago, and the ability to transform lives still drives her to this day. For more than 100 years, Lundbeck has been at the forefront of […]

Profiles in Pharma – October 1, 2021

Malin Parkler – Passionate about science, health & leadership

Malin Parkler, CEO of Pfizer Sweden, is driven by curiosity and a passion to build knowledge and evolve the life science industry – with the ultimate goal to yield real benefits for patients. Rarely has the world been more in need of leaders. As the global community struggled with the COVID-19 pandemic last year, people […]

Profiles in Pharma – August 15, 2019

Katarina Ageborg, CEO AstraZeneca Sweden

Few companies are as synonymous with Sweden as AstraZeneca and few CEOs as visible. Yet, Katarina Ageborg, AstraZeneca Sweden’s new CEO, prefers not to think about being center stage, but instead about what her position can do for the company, Sweden and the pharmaceutical industry as a whole. “I don’t think about it that way […]

Profiles in Pharma – July 1, 2017

Embracing diversity – for the sake of true innovation

Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief in the need for diversity to truly bring forth innovation. A view that is also deeply incorporated in her job as Head of MedImmune. Editor’s note: In 2019 Bahika Jallal left MedImmune and became the […]

Profiles in Pharma – March 22, 2017

“The scientist in me wants to make a difference”

After ten years of diabetes research and development at Novo Nordisk, Dorte X. Gram took her findings and work further to start something on her own. As founder and CEO of PILA PHARMA she hopes to bring a new oral anti-diabetic agent to the market. What made you take the leap to go on your […]

Profiles in Pharma – March 8, 2017

“We have to embrace the new era of diabetes care”

Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer at Novo Nordisk, talks about the Danish pharma giant’s drug-development strategy, the new era of diabetes care and his 25 year-long passion for his job. The changing diabetes market, with increasing competition and high prices for diabetes products in the US, has made the world’s […]

Profiles in Pharma – February 16, 2017

From regulator to pharma industry specialist

Dr. Thomas Lönngren, former head of the EMA and today a pharmaceutical consultant, provides some insights on the aftermath of Brexit, describes current challenges the industry is facing and takes a short walk down memory lane on his career journey. The summer of 2016 will be remembered for many things; record temperatures, terrorist acts in […]

Profiles in Pharma – April 21, 2014

Jan Lundberg: The long view of R&D at Eli Lilly

Like sports, R&D requires team spirit, commitment, and a long view says Dr. Jan Lundberg, Lilly executive vice president for science and technology, and president of Lilly Research Laboratories. Dr. Jan Lundberg’s online bios and YouTube videos portray a steely pharmaceutical executive whose idea of fun is a 90 km ski race. It’s all true. […]